#BEGIN_DRUGCARD DB06147

# AHFS_Codes:
Not Available

# ATC_Codes:
D06BA02
J01EB07

# Absorption:
Not Available

# Biotransformation:
Metabolism of sulfonamide drugs in animals includes conjugation at the N4-position (acetyl, sulfate, glucuronic acid, and glucose), conjugation at the N1-position (sulfate and glucuronic acid), removal of the p-amino group (formation of the desamino metabolite), ring hydroxylation, and conjugation of the ring hydroxylation products. Dietary nitrite enhances the production of the desamino metabolite of sulfathiazole. The intermediate leading to the desamino metabolite of sulfamethazine is weakly mutagenic in the Ames test (Nelson et al., 1987; Paulson et al., 1987).

# Brand_Mixtures:
Not Available

# Brand_Names:
Neo-Strepsan

# CAS_Registry_Number:
72-14-0

# ChEBI_ID:
9337

# Chemical_Formula:
C9H9N3O2S2

# Chemical_IUPAC_Name:
4-amino-N-(1,3-thiazol-2-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2007-11-19 10:59:06 -0700

# DPD_Drug_ID_Number:
Not Available

# Description:
Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents

# Drug_Interactions:
Methenamine mandelate	Possible crystallization of urates with this combination
Methotrexate	The sulfamide increases the toxicity of methotrexate

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.05

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
373 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfathiazole

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)

# InChI_Key:
InChIKey=JNMRHUJNCSQMMB-UHFFFAOYSA-N

# Indication:
Sulfathiazole is effective against a wide range of gram positive and gram negative pathogenic microorganisms. Although no longer used in humans, it is used in cattle.

# KEGG_Compound_ID:
C11169

# KEGG_Drug_ID:
D01047

# LIMS_Drug_ID:
6148

# Mechanism_Of_Action:
Not Available

# Melting_Point:
189 °C

# Molecular_Weight_Avg:
255.317

# Molecular_Weight_Mono:
255.013617927

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA165958356

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.88

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
9.21e-01 g/l

# Primary_Accession_No:
DB06147

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Sodium sulfathiazole
Sulphathiazole

# Synthesis_Reference:
Not Available

# Toxicity:
Acute oral toxicity (LD50): 4500 mg/kg [Mouse].

# Update_Date:
2013-02-08 16:24:30 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sulfathiazole

# pKa_Isoelectric_Point:
7.2

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP19A1

# Phase_1_Metabolizing_Enzyme_1_ID:
3811

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 19A1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 19A1
MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLI
SHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKL
GLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTN
ESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWL
YKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCI
LEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFI
YESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAK
NVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLH
PDETKNMLEMIFTPRNSDRCLEH

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11511

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
2694948	Nichols BP, Guay GG: Gene amplification contributes to sulfonamide resistance in Escherichia coli. Antimicrob Agents Chemother. 1989 Dec;33(12):2042-8.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z30658

# Drug_Target_1_GenBank_ID_Protein:
505177

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>1115 bp
TGATACCCGAATATAAGCATAATGTTTTAAATAATACCATCAGATGTTTATATAACAAAT
ATGTGAGTAGGATGAAAGAACAATATAATATAAATATTAAAGAAAATAATAAAAGGATAT
ATGTATTAAAAGATAGAATTTCTTATTTAAAAGAAAAAACAAATATTGTTGGAATATTAA
ATGTTAATTATGATTCTTTTTCAGATGGAGGTATTTTTGTTGAACCTAAACGTGCTGTTC
AAAGAATGTTTGAAATGATAAATGAAGGTGCTAGTGTTATAGATATAGGTGGAGAATCCG
CTGGTCCTTTTGTTATACCTAATCCAAAAATTAGTGAAAGAGATTTAGTAGTACCTGTAT
TACAATTATTTCAAAAAGAATGGAATGATATAAAAAATAAAATTGTTAAATGTGATGCGA
AACCAATTATAAGTATTGATACAATTAACTATAATGTTTTTAAAGAATGTGTTGATAATG
ATTTAGTTGATATATTAAATGATATTAGTGCTTGTACAAATAATCCAGAAATTATAAAAT
TATTAAAAAAAAAAAACAAATTCTATAGTGTAGTTCTAATGCATAAAAGAGGAAATCCAC
ATACAATGGATAAACTAACAAATTATGATAATCTAGTTTATGATATAAAAAATTATTTAG
AACAAAGATTAAATTTTCTTGTATTAAATGGAATACCTCGTTATAGGATACTATTTGATA
TTGGATTAGGATTTGCGAAGAAACATGATCAATCTATTAAACTCTTACAAAATATACATG
TATATGATGAGTATCCACTTTTTATTGGATATTCAAGAAAAAGATTTATTGCCCATTGCA
TGAATGATCAAAATGTTGTAATAAATACACAACAAAAATTACATGATGAACAACAAAATG
AAAATAAAAATATTGTGGACAAATCACACAATTGGATGTTTCAGATGAATTACATGAGGA
AAGACAAGGATCAACTTTTATATCAAAAAAATATATGTGGTGGATTAGCAATTGCTTCCT
ACAGCTATTATAAAAAGGTAGATCTAATAAGAGTTCATGACGTTTTAGAAACAAAATCGG
TTTTGGATGTTTTAACAAAAATAGACCAAGTGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
7925353	Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994 Sep 1;224(2):397-405.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4116

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43372

# Drug_Target_1_Name:
Dihydropteroate synthetase

# Drug_Target_1_Number_of_Residues:
370

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthetase
IPEYKHNVLNNTIRCLYNKYVSRMKEQYNINIKENNKRIYVLKDRISYLKEKTNIVGILN
VNYDSFSDGGIFVEPKRAVQRMFEMINEGASVIDIGGESAGPFVIPNPKISERDLVVPVL
QLFQKEWNDIKNKIVKCDAKPIISIDTINYNVFKECVDNDLVDILNDISACTNNPEIIKL
LKKKNKFYSVVLMHKRGNPHTMDKLTNYDNLVYDIKNYLEQRLNFLVLNGIPRYRILFDI
GLGFAKKHDQSIKLLQNIHVYDEYPLFIGYSRKRFIAHCMNDQNVVINTQQKLHDEQQNE
NKNIVDKSHNWMFQMNYMRKDKDQLLYQKNICGGLAIASYSYYKKVDLIRVHDVLETKSV
LDVLTKIDQV

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q27738

# Drug_Target_1_SwissProt_Name:
Q27738_PLAFA

# Drug_Target_1_Synonyms:
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
9.19

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB06147
